Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 79 articles:
HTML format



Single Articles


    January 2024
  1. AGGARWAL R, Heller G, Hillman DW, Xiao H, et al
    PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    J Clin Oncol. 2024 Jan 23:JCO2301157. doi: 10.1200/JCO.23.01157.
    PubMed     Abstract available


  2. CHILDS DS, Orme JJ, Ravi P
    Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
    J Clin Oncol. 2024 Jan 23:JCO2302410. doi: 10.1200/JCO.23.02410.
    PubMed    


  3. HALABI S, Roy A, Rydzewska L, Guo S, et al
    Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535.
    PubMed     Abstract available


  4. DENMEADE SR
    Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2302310. doi: 10.1200/JCO.23.02310.
    PubMed    


    December 2023
  5. FALLAH J, Xu J, Weinstock C, Brave MH, et al
    FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Dec 21:JCO2301868. doi: 10.1200/JCO.23.01868.
    PubMed     Abstract available


    November 2023
  6. MATEO J, de Bono JS, Fizazi K, Saad F, et al
    Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
    PubMed     Abstract available


  7. ROY S, Romero T, Michalski JM, Feng FY, et al
    Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
    J Clin Oncol. 2023;41:5005-5014.
    PubMed     Abstract available


  8. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Nov 6:JCO2302128. doi: 10.1200/JCO.23.02128.
    PubMed     Abstract available


  9. TAGAWA ST, Thomas C, Sartor AO, Sun M, et al
    Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591.
    J Clin Oncol. 2023 Nov 3:JCO2300573. doi: 10.1200/JCO.23.00573.
    PubMed     Abstract available


    October 2023
  10. GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al
    Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
    J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949.
    PubMed     Abstract available


  11. MADAN RA, Karzai F, VanderWeele DJ, Cheng HH, et al
    Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
    J Clin Oncol. 2023 Oct 17:JCO2301502. doi: 10.1200/JCO.23.01502.
    PubMed    


    September 2023
  12. FRANCOLINI G, Gaetano Allegra A, Detti B, Di Cataldo V, et al
    Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).
    J Clin Oncol. 2023 Sep 21:JCO2300985. doi: 10.1200/JCO.23.00985.
    PubMed     Abstract available


  13. STAR J, Bandi P, Siegel RL, Han X, et al
    Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.
    J Clin Oncol. 2023;41:4352-4359.
    PubMed     Abstract available


    August 2023
  14. SLOVIN SF, Knudsen K, Halabi S, de Leeuw R, et al
    Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Aug 15:JCO2202639. doi: 10.1200/JCO.22.02639.
    PubMed     Abstract available


  15. MAI Z, Yan W, Zhou Y
    Several Questions About Prostate-Specific Antigen and Salvage Radiotherapy After Radical Prostatectomy.
    J Clin Oncol. 2023;41:3956.
    PubMed    


    July 2023
  16. DAI C, Dehm SM, Sharifi N
    Targeting the Androgen Signaling Axis in Prostate Cancer.
    J Clin Oncol. 2023 Jul 10:JCO2300433. doi: 10.1200/JCO.23.00433.
    PubMed     Abstract available


  17. STOPSACK KH, Mucci LA, Giovannucci EL
    Aggressive Prostate Cancer Is Preventable and so Are Racial Disparities.
    J Clin Oncol. 2023 Jul 10:JCO2300507. doi: 10.1200/JCO.23.00507.
    PubMed    


  18. ROACH M 3RD, Chapman C, Coleman PW
    Racism Might Cause Prostate Cancer and Definitely Causes Excess Unemployment, Lost Wages, and Excess Cancer Deaths.
    J Clin Oncol. 2023 Jul 10:JCO2300502. doi: 10.1200/JCO.23.00502.
    PubMed    


    June 2023
  19. MICHALSKI JM, Winter KA, Prestidge BR, Sanda MG, et al
    Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
    J Clin Oncol. 2023 Jun 14:JCO2201856. doi: 10.1200/JCO.22.01856.
    PubMed     Abstract available


  20. ANTONARAKIS ES, Park SH, Goh JC, Shin SJ, et al
    Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
    J Clin Oncol. 2023 Jun 8:JCO2300233. doi: 10.1200/JCO.23.00233.
    PubMed     Abstract available


  21. WALA J, Nguyen P, Pomerantz M
    Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2023 Jun 2:JCO2300723. doi: 10.1200/JCO.23.00723.
    PubMed     Abstract available


    May 2023
  22. HINDIE E
    Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2023 May 31:JCO2300686. doi: 10.1200/JCO.23.00686.
    PubMed    


  23. ABNER A, Vicini F
    Regarding Sequencing of Androgen-Deprivation Therapy.
    J Clin Oncol. 2023;41:2448-2449.
    PubMed    


    April 2023
  24. KRAUSS DJ, Karrison T, Martinez AA, Morton G, et al
    Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
    J Clin Oncol. 2023 Apr 27:JCO2202390. doi: 10.1200/JCO.22.02390.
    PubMed     Abstract available


  25. MOVSAS B, Rodgers JP, Elshaikh MA, Martinez AA, et al
    Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
    J Clin Oncol. 2023 Apr 27:JCO2202389. doi: 10.1200/JCO.22.02389.
    PubMed     Abstract available


  26. MARSHALL CH
    Acting on Actionable Mutations in Metastatic Prostate Cancer.
    J Clin Oncol. 2023 Apr 25:JCO2300350. doi: 10.1200/JCO.23.00350.
    PubMed     Abstract available


  27. HALABI S, Yang Q, Roy A, Luo B, et al
    External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Apr 11:JCO2202661. doi: 10.1200/JCO.22.02661.
    PubMed     Abstract available


  28. DORFF T, Tripathi A
    Incorporating Prognostic Models Into Clinical Practice for Patients With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Apr 11:JCO2300374. doi: 10.1200/JCO.23.00374.
    PubMed    


  29. VIRGO KS, Rumble RB, Talcott J
    Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
    J Clin Oncol. 2023 Apr 3:JCO2300155. doi: 10.1200/JCO.23.00155.
    PubMed    


    March 2023
  30. MORRIS MJ, Heller G, Hillman DW, Bobek O, et al
    Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
    J Clin Oncol. 2023 Mar 30:JCO2202394. doi: 10.1200/JCO.22.02394.
    PubMed     Abstract available


  31. ANTONARAKIS ES, Abida W
    Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?
    J Clin Oncol. 2023 Mar 23:JCO2300270. doi: 10.1200/JCO.23.00270.
    PubMed    


  32. CHI KN, Rathkopf D, Smith MR, Efstathiou E, et al
    Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Mar 23:JCO2201649. doi: 10.1200/JCO.22.01649.
    PubMed     Abstract available


  33. MCMANUS HD, Armstrong AJ
    The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2023 Mar 22:JCO2300323. doi: 10.1200/JCO.23.00323.
    PubMed    


  34. TILKI D, Chen MH, Wu J, Huland H, et al
    Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2023 Mar 1:JCO2202489. doi: 10.1200/JCO.22.02489.
    PubMed     Abstract available


    February 2023
  35. HUSSAIN M, Tombal B, Saad F, Fizazi K, et al
    Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    J Clin Oncol. 2023 Feb 16:JCO2300041. doi: 10.1200/JCO.23.00041.
    PubMed     Abstract available


  36. GILLESSEN S, Procopio G, Hayoz S, Kremer E, et al
    Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
    J Clin Oncol. 2023 Feb 8:JCO2201726. doi: 10.1200/JCO.22.01726.
    PubMed     Abstract available


    January 2023
  37. VICKERS AJ, Mahal B, Ogunwobi OO
    Racism Does Not Cause Prostate Cancer, It Causes Prostate Cancer Death.
    J Clin Oncol. 2023 Jan 24:JCO2202203. doi: 10.1200/JCO.22.02203.
    PubMed    


    December 2022
  38. NYBERG T, Brook MN, Ficorella L, Lee A, et al
    CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
    J Clin Oncol. 2022 Dec 9:JCO2201453. doi: 10.1200/JCO.22.01453.
    PubMed     Abstract available


  39. BABOUDJIAN M, Roupret M, Ploussard G
    Redefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Perspective.
    J Clin Oncol. 2022 Dec 2:JCO2201621. doi: 10.1200/JCO.22.01621.
    PubMed    


    November 2022
  40. TRAN PT, Lowe K, Tsai HL, Song DY, et al
    Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
    J Clin Oncol. 2022 Nov 11:JCO2201662. doi: 10.1200/JCO.22.01662.
    PubMed     Abstract available


    October 2022
  41. MA TM, Sun Y, Malone S, Roach M 3rd, et al
    Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
    J Clin Oncol. 2022 Oct 21:JCO2200970. doi: 10.1200/JCO.22.00970.
    PubMed     Abstract available


  42. KIM JW, McKay RR, Radke MR, Zhao S, et al
    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947.
    PubMed     Abstract available


    September 2022
  43. EPSTEIN JI, Kibel AS
    Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care.
    J Clin Oncol. 2022;40:3106-3109.
    PubMed    


  44. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation.
    J Clin Oncol. 2022 Sep 16:JCO2201865. doi: 10.1200/JCO.22.01865.
    PubMed     Abstract available


    August 2022
  45. DEEK MP, Van der Eecken K, Sutera P, Deek RA, et al
    Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
    J Clin Oncol. 2022 Aug 24:JCO2200644. doi: 10.1200/JCO.22.00644.
    PubMed     Abstract available


  46. SUN R, Wei LJ
    Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Aug 19:JCO2201084. doi: 10.1200/JCO.22.01084.
    PubMed    


    July 2022
  47. TISSEVERASINGHE S, Tolba M, Saad F, Gravis G, et al
    Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
    J Clin Oncol. 2022 Jul 21:JCO2200883. doi: 10.1200/JCO.22.00883.
    PubMed    


    June 2022
  48. JACKSON WC, Tang M, Schipper MJ, Sandler HM, et al
    Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
    J Clin Oncol. 2022 Jun 23:JCO2102741. doi: 10.1200/JCO.21.02741.
    PubMed     Abstract available


  49. KARTOLO A, Tannock IF, Vera Badillo FE
    Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    J Clin Oncol. 2022 Jun 20:JCO2200705. doi: 10.1200/JCO.22.00705.
    PubMed    


  50. MADAN RA, Mena E, Lindenberg L, Choyke PL, et al
    With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
    J Clin Oncol. 2022 Jun 3:JCO2200493. doi: 10.1200/JCO.22.00493.
    PubMed    


  51. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available


    May 2022
  52. CAO Y, Deville C Jr
    Adjuvant Radiation for Pathologically Node-Positive Prostate Cancer: Evidence When Early Salvage May Not Be Early Enough.
    J Clin Oncol. 2022 May 23:JCO2200645. doi: 10.1200/JCO.22.00645.
    PubMed    


    April 2022
  53. AGARWAL N, Tangen CM, Hussain MHA, Gupta S, et al
    Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
    J Clin Oncol. 2022 Apr 21:JCO2102517. doi: 10.1200/JCO.21.02517.
    PubMed     Abstract available


  54. HUSSAIN M, Carducci MA, Clarke N, Fenton SE, et al
    Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
    J Clin Oncol. 2022 Apr 19:JCO2200208. doi: 10.1200/JCO.22.00208.
    PubMed    


  55. EGGENER SE, Berlin A, Vickers AJ, Paner GP, et al
    Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
    J Clin Oncol. 2022 Apr 18:JCO2200123. doi: 10.1200/JCO.22.00123.
    PubMed    


  56. ARMSTRONG AJ, Azad AA, Iguchi T, Szmulewitz RZ, et al
    Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200193. doi: 10.1200/JCO.22.00193.
    PubMed     Abstract available


    March 2022
  57. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2022 Mar 15:JCO2102800. doi: 10.1200/JCO.21.02800.
    PubMed     Abstract available


    February 2022
  58. PATEL NA, Reiter RE
    Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.
    J Clin Oncol. 2022 Feb 24:JCO2102940. doi: 10.1200/JCO.21.02940.
    PubMed    


  59. VAN WAMBEKE S, Vera-Badillo FE, Gyawali B
    Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
    J Clin Oncol. 2022 Feb 21:JCO2102304. doi: 10.1200/JCO.21.02304.
    PubMed    


    January 2022
  60. SCHODER H, Hope TA, Knopp M, Kelly WK, et al
    Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
    J Clin Oncol. 2022 Jan 11:JCO2102440. doi: 10.1200/JCO.21.02440.
    PubMed     Abstract available


  61. MORGANS AK, Beltran H
    Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2022 Jan 6:JCO2102530. doi: 10.1200/JCO.21.02530.
    PubMed     Abstract available


  62. DZIMITROWICZ HE, Armstrong AJ
    Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
    J Clin Oncol. 2022 Jan 6:JCO2102504. doi: 10.1200/JCO.21.02504.
    PubMed    


    December 2021
  63. STOCKLER MR, Martin AJ, Davis ID, Dhillon HM, et al
    Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
    J Clin Oncol. 2021 Dec 20:JCO2100941. doi: 10.1200/JCO.21.00941.
    PubMed     Abstract available


    November 2021
  64. RUSH HL, Murphy L, Morgans AK, Clarke NW, et al
    Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
    J Clin Oncol. 2021 Nov 10:JCO2100728. doi: 10.1200/JCO.21.00728.
    PubMed     Abstract available


  65. SADA YH
    A Dozen Eggs.
    J Clin Oncol. 2021;39:3645-3646.
    PubMed    


    September 2021
  66. KERKMEIJER LGW, Pos FJ, Haustermans K, van der Heide UA, et al
    Reply to I. R. Vogelius et al.
    J Clin Oncol. 2021;39:3086-3087.
    PubMed    


    July 2021
  67. BOLLA M, Neven A, Maingon P, Carrie C, et al
    Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
    J Clin Oncol. 2021 Jul 26:JCO2100855. doi: 10.1200/JCO.21.00855.
    PubMed     Abstract available


  68. SPERGER JM, Emamekhoo H, McKay RR, Stahlfeld CN, et al
    Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    J Clin Oncol. 2021 Jul 1:JCO2100169. doi: 10.1200/JCO.21.00169.
    PubMed     Abstract available


  69. D'AMICO AV, Xie W, McMahon E, Loffredo M, et al
    Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
    J Clin Oncol. 2021 Jul 1:JCO2100596. doi: 10.1200/JCO.21.00596.
    PubMed     Abstract available


    June 2021
  70. VOGELIUS IR, Bentzen SM
    Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?
    J Clin Oncol. 2021 Jun 4:JCO2100586. doi: 10.1200/JCO.21.00586.
    PubMed    


  71. YANG DD, Nguyen PL, D'Amico AV
    Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited.
    J Clin Oncol. 2021 Jun 4:JCO2100621. doi: 10.1200/JCO.21.00621.
    PubMed    


  72. BRENNEMAN RJ, Baumann BC, Gay HA, Michalski JM, et al
    Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Jun 4:JCO2100634. doi: 10.1200/JCO.21.00634.
    PubMed    


  73. DESS RT, Jackson WC, Spratt DE
    End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?
    J Clin Oncol. 2021 Jun 4:JCO2100376. doi: 10.1200/JCO.21.00376.
    PubMed    


  74. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2021 Jun 4:JCO2003714. doi: 10.1200/JCO.20.03714.
    PubMed     Abstract available


    May 2021
  75. TEWARI AK, Gillessen S, Sweeney CJ
    Metastatic Prostate Cancer: In Search of More Granularity.
    J Clin Oncol. 2021 May 14:JCO2100643. doi: 10.1200/JCO.21.00643.
    PubMed    


    April 2021
  76. HOCHT S, Mason M, Wiegel T
    Timing of ADT in Radiotherapy of Prostate Cancer.
    J Clin Oncol. 2021 Apr 29:JCO2100032. doi: 10.1200/JCO.21.00032.
    PubMed    


  77. CHI KN, Chowdhury S, Bjartell A, Chung BH, et al
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    J Clin Oncol. 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
    PubMed     Abstract available


  78. MURPHY AB, Abern MR, Liu L, Wang H, et al
    Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.
    J Clin Oncol. 2021 Apr 9:JCO2002997. doi: 10.1200/JCO.20.02997.
    PubMed     Abstract available


    January 2021
  79. SPRATT DE, Malone S, Roy S, Grimes S, et al
    Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
    J Clin Oncol. 2021;39:136-144.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.